Ocrelizumab/EM: Embarazo y Lactancia

• P1231 - Understanding the Experiences of Neurologists Treating Women with MS and their Perspectives about Family Planning with MS in Europe and the United States Seetasith A, et al. 

Ocrelizumab/EM: Administración subcutánea

• P1640 - Characteristics of Patients Starting Ocrelizumab Subcutaneous in Denmark, Germany, and the United Kingdom Braune S, et al. 

Ocrelizumab/EM: Real-world data

• P1757 - Ocrelizumab (OCR) stabilizes and even improves fatigue in the majority of patients with relapsing MS after 24 months: Key findings from the second interim analysis of the observational study MoOzaRt Penner I-K, et al. 

Ocrelizumab/EM: Biomarcadores 

• P1784 - Patient Satisfaction and Neurofilament Light Chain Levels in Persons With MS Following Subcutaneous Ocrelizumab in the Prospective SurfSubQ Study: Baseline Data Pawlitzki M, et al. 

Ocrelizumab/EM: Embarazo 

• 16:30-18:30 | P084 
  Maternal and Infant Pregnancy Outcomes in Women With MS Who Received Ocrelizumab Versus a Comparator MS Population: Results of the Ocrelizumab Pregnancy Registry Hellwig K, et al. 

Ocrelizumab/EM: Poblaciones desatendidas

• 16:30-18:30 | P115
  Associations Between Comorbidities, Disease Activity and Response to Ocrelizumab in the CHIMES Trial Reder AT, et al. 

Ocrelizumab/EM: Real-world data 

• 16:30-18:30 | P295
  Long-Term Surveillance of Ocrelizumab-Treated Patients With Multiple Sclerosis – Interim Comparative Safety Analysis Butzkueven H, et al. 
• 16:30-18:30 | P301
  Ocrelizumab treatment shows a quantitative reduction of peripheral immunoglobulin levels but does not significantly alter the qualitative composition of immunoglobulin repertoires within 3 years of treatment Vasilenko N, et al. 

Ocrelizumab/EM: Administración subcutanea

• 16:30-18:30 | P307
  Ocrelizumab subcutaneous: final analysis of the OCARINA II study Newsome SD, et al. 

Ocrelizumab/EM: Embarazo y Lactancia 

• 14:35-14:45 | O102
  Humoral Responses and 1-Year Follow Up of Infants Potentially Exposed to Ocrelizumab During Pregnancy and Breastfeeding: Final Analysis of the Prospective, Multicentre, Open-Label, Phase IV Studies MINORE and SOPRANINO Bove R, et al. 

Ocrelizumab/EM: Data Pediátrica 

• 15:15-15:25 | O106
  Ocrelizumab Dose Selection for Treatment of Paediatric Relapsing-Remitting Multiple Sclerosis: Long-Term 96-Week Safety and Efficacy Results of the Phase II OPERETTA 1 Study Waubant E, et al. 

Ocrelizumab/EM: Biomarcadores

• P197 - Sustained Serum Neurofilament Light Chain Reduction and Clinical Outcomes With LongTerm Ocrelizumab Treatment in OPERA I and ORATORIO Trials and Their Open-Label Extensions in Relapsing and Primary Progressive MS Kuhle J, et al. 

Ocrelizumab/EM: Embarazo 

• P589 - Real-World Patterns of Ocrelizumab and Other Disease-Modifying Therapy Utilization Before, During and After Pregnancy in Women with Multiple Sclerosis: A Retrospective ClaimsBased Cohort Study Houtchens MK, et al. 

Ocrelizumab/EM: Real-world data 

• P864 -Work Productivity and Activity Impairment (WPAI) Outcomes From Working Persons With Relapsing MS Treated With Ocrelizumab in the German Real-World Study CONFIDENCE Buttmann M, et al. 

Ocrelizumab/EM: Eficacia en EM y progresión en EMPP

• 10:35-10:45| O128 - Ocrelizumab vs placebo in primary progressive MS: efficacy and safety results of the Phase IIIb ORATORIO-HAND study Giovannoni G, et al. 
• 10:45-10:55 | O129 - Efficacy and safety of a body-weight–adjusted high dose of ocrelizumab vs standard dose in PPMS: primary results of the Phase IIIb GAVOTTE study Hauser S, et al. 

Ocrelizumab/EM: Data en Pediatría 

• 10:55-11:05 | O130 - Efficacy and safety of ocrelizumab compared with fingolimod in paediatric relapsing-remitting MS: results of the Phase III OPERETTA 2 study Banwell B, et al.